vs

Side-by-side financial comparison of PREFORMED LINE PRODUCTS CO (PLPC) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.

PREFORMED LINE PRODUCTS CO is the larger business by last-quarter revenue ($173.1M vs $170.6M, roughly 1.0× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 4.9%, a 72.3% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 3.6%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $11.8M).

Preformed Line Products Co (PLPC) designs, manufactures and supplies engineered hardware for power transmission, telecommunications, and renewable energy infrastructure sectors. It serves utility, network operator and industrial customers across global regions, offering solutions that boost network reliability and operational efficiency.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.

PLPC vs PTGX — Head-to-Head

Bigger by revenue
PLPC
PLPC
1.0× larger
PLPC
$173.1M
$170.6M
PTGX
Growing faster (revenue YoY)
PTGX
PTGX
+180.8% gap
PTGX
184.4%
3.6%
PLPC
Higher net margin
PTGX
PTGX
72.3% more per $
PTGX
77.2%
4.9%
PLPC
More free cash flow
PTGX
PTGX
$171.0M more FCF
PTGX
$182.8M
$11.8M
PLPC

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
PLPC
PLPC
PTGX
PTGX
Revenue
$173.1M
$170.6M
Net Profit
$8.4M
$131.7M
Gross Margin
29.8%
Operating Margin
6.8%
74.3%
Net Margin
4.9%
77.2%
Revenue YoY
3.6%
184.4%
Net Profit YoY
-19.3%
381.7%
EPS (diluted)
$1.72
$2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLPC
PLPC
PTGX
PTGX
Q4 25
$173.1M
Q3 25
$178.1M
Q2 25
$169.6M
Q1 25
$148.5M
Q4 24
$167.1M
$170.6M
Q3 24
$147.0M
Q2 24
$138.7M
Q1 24
$140.9M
$255.0M
Net Profit
PLPC
PLPC
PTGX
PTGX
Q4 25
$8.4M
Q3 25
$2.6M
Q2 25
$12.7M
Q1 25
$11.5M
Q4 24
$10.5M
$131.7M
Q3 24
$7.7M
Q2 24
$9.4M
Q1 24
$9.6M
$207.3M
Gross Margin
PLPC
PLPC
PTGX
PTGX
Q4 25
29.8%
Q3 25
29.7%
Q2 25
32.7%
Q1 25
32.8%
Q4 24
33.3%
Q3 24
31.1%
Q2 24
31.9%
Q1 24
31.3%
Operating Margin
PLPC
PLPC
PTGX
PTGX
Q4 25
6.8%
Q3 25
7.4%
Q2 25
10.1%
Q1 25
8.8%
Q4 24
10.5%
74.3%
Q3 24
7.1%
Q2 24
8.1%
Q1 24
8.2%
80.9%
Net Margin
PLPC
PLPC
PTGX
PTGX
Q4 25
4.9%
Q3 25
1.5%
Q2 25
7.5%
Q1 25
7.8%
Q4 24
6.3%
77.2%
Q3 24
5.2%
Q2 24
6.8%
Q1 24
6.8%
81.3%
EPS (diluted)
PLPC
PLPC
PTGX
PTGX
Q4 25
$1.72
Q3 25
$0.53
Q2 25
$2.56
Q1 25
$2.33
Q4 24
$2.13
$2.01
Q3 24
$1.54
Q2 24
$1.89
Q1 24
$1.94
$3.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLPC
PLPC
PTGX
PTGX
Cash + ST InvestmentsLiquidity on hand
$418.9M
Total DebtLower is stronger
$38.3M
Stockholders' EquityBook value
$475.5M
$675.3M
Total Assets
$653.6M
$744.7M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLPC
PLPC
PTGX
PTGX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$418.9M
Q3 24
Q2 24
Q1 24
$322.6M
Total Debt
PLPC
PLPC
PTGX
PTGX
Q4 25
$38.3M
Q3 25
$36.0M
Q2 25
$31.8M
Q1 25
$29.1M
Q4 24
$20.8M
Q3 24
$27.2M
Q2 24
$31.6M
Q1 24
$55.0M
Stockholders' Equity
PLPC
PLPC
PTGX
PTGX
Q4 25
$475.5M
Q3 25
$466.3M
Q2 25
$460.7M
Q1 25
$435.8M
Q4 24
$422.3M
$675.3M
Q3 24
$429.0M
Q2 24
$416.2M
Q1 24
$413.4M
$560.4M
Total Assets
PLPC
PLPC
PTGX
PTGX
Q4 25
$653.6M
Q3 25
$644.6M
Q2 25
$631.5M
Q1 25
$592.5M
Q4 24
$573.9M
$744.7M
Q3 24
$592.0M
Q2 24
$572.6M
Q1 24
$586.1M
$629.3M
Debt / Equity
PLPC
PLPC
PTGX
PTGX
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.07×
Q1 25
0.07×
Q4 24
0.05×
Q3 24
0.06×
Q2 24
0.08×
Q1 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLPC
PLPC
PTGX
PTGX
Operating Cash FlowLast quarter
$21.9M
$184.2M
Free Cash FlowOCF − Capex
$11.8M
$182.8M
FCF MarginFCF / Revenue
6.8%
107.1%
Capex IntensityCapex / Revenue
5.9%
0.8%
Cash ConversionOCF / Net Profit
2.60×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$33.3M
$101.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLPC
PLPC
PTGX
PTGX
Q4 25
$21.9M
Q3 25
$18.9M
Q2 25
$26.9M
Q1 25
$5.7M
Q4 24
$24.1M
$184.2M
Q3 24
$9.4M
Q2 24
$28.3M
Q1 24
$5.8M
$-27.4M
Free Cash Flow
PLPC
PLPC
PTGX
PTGX
Q4 25
$11.8M
Q3 25
$8.3M
Q2 25
$18.6M
Q1 25
$-5.3M
Q4 24
$20.6M
$182.8M
Q3 24
$5.8M
Q2 24
$24.6M
Q1 24
$1.8M
$-27.7M
FCF Margin
PLPC
PLPC
PTGX
PTGX
Q4 25
6.8%
Q3 25
4.7%
Q2 25
10.9%
Q1 25
-3.6%
Q4 24
12.3%
107.1%
Q3 24
3.9%
Q2 24
17.7%
Q1 24
1.3%
-10.9%
Capex Intensity
PLPC
PLPC
PTGX
PTGX
Q4 25
5.9%
Q3 25
6.0%
Q2 25
4.9%
Q1 25
7.4%
Q4 24
2.1%
0.8%
Q3 24
2.4%
Q2 24
2.7%
Q1 24
2.8%
0.1%
Cash Conversion
PLPC
PLPC
PTGX
PTGX
Q4 25
2.60×
Q3 25
7.21×
Q2 25
2.12×
Q1 25
0.49×
Q4 24
2.30×
1.40×
Q3 24
1.22×
Q2 24
3.02×
Q1 24
0.60×
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons